VISTA抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using VISTA mouse mAb (green) and negative control (red).    

  
  

VISTA (V-domain Ig suppressor of T-cell activation), also known as PD-1H or DD1α, is an immune checkpoint protein identified in 2011 as a critical regulator of T-cell function. Structurally, it belongs to the B7 family of immunomodulatory molecules and is expressed on myeloid cells, regulatory T cells (Tregs), and activated T cells. Unlike PD-1 or CTLA-4. VISTA functions as both a ligand and receptor, primarily suppressing T-cell activation and cytokine production. It plays a dual role in maintaining immune tolerance and promoting tumor immune evasion by creating an immunosuppressive microenvironment.

Preclinical studies highlight its overexpression in various cancers, correlating with poor prognosis and resistance to existing immunotherapies. VISTA inhibitors, including monoclonal antibodies and small molecules, are under investigation to block its immunosuppressive signals and enhance antitumor immunity. Early-phase clinical trials suggest potential in treating "cold" tumors unresponsive to PD-1/PD-L1 therapies. However, challenges remain, such as understanding its complex signaling mechanisms and optimizing combination strategies with other therapies. VISTA represents a promising yet underexplored target in the evolving landscape of cancer immunotherapy.